- SEK 72m follow-up order (Terminals) from Swedish FMV - Deliveries start in Q3 - Could add ~10% to ...
Active Biotech har tagit ett steg närmre ett partnerskap i och med slutförandet av LION-studien.
Redeye comments on Vertiseit’s acquisition of MDT. As the price is reasonable and the SEK20m in ARR ...
Redeye comments on Isofol’s recently announced rights issue outcome.
According to the press release yesterday, the Board of Directors and Julian Read came to the mutual ...
Avtech reported preliminary Q2 2025 net sales of SEK11.
Hyresintäkterna steg med 62% till 15,2 meur och förvaltningsresultat ökade med över 50% till 7,9 meu...
- Expect continued order recovery but flat sales y-o-y - M&A resumed, 1.
- Expect strong sales of SEK 29m supported by intra-quarter deliveries - Order influx encouraging, b...
Redeye comments on the SEK29.4m rights issue of units and the restructuring initiatives by reducing ...
3.5m EEs, sales -13% (-8% FX), EBIT margin 36.2% (+5.
Redeye judges that FluoGuide’s recently released progress update mostly confirms our expectations.
Duell’s Q3 figures were anticipated to be weak following the profit warning.
-20% organic growth in Q2e due to last year's radio order Global military peer estimates remain flat...
Market remains muted, but new contracts are positive Targets challenging (earnings likely to land be...
